2022_Oct_PDA_Universe_CA_leaderboard

Lexaria Bioscience

Lexaria Bioscience develops innovative drug delivery platforms including the patented DehydraTECH™ for the delivery of lipophilic molecules. DehydraTECH™ increases bio-absorption, reduces time of onset, and can reduce drug costs for orally administered bioactives.


Visit Website

Headquarters
#100-740 McCurdy Rd
Kelowna, BC
V1X2P7

Phone / Contact

T: 250-765-6424

Connect

Lexaria Bioscience develops innovative drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way API’s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

Top